Fusion Biopsy Market Size, Share & Trends Report

Fusion Biopsy Market Size, Share & Trends Analysis Report By Biopsy Route (Transrectal, Transperineal), By End-use (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68038-844-2
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Market Segmentation

  • Fusion Biopsy Route Outlook (Revenue, USD Million, 2018 - 2030)
    • Transrectal
    • Transperineal
  • Fusion Biopsy End-use Outlook (Revenue, USD Million, 2018 - 2030)
    • Hospitals
    • Diagnostic centers
    • Ambulatory care centers
  • Fusion Biopsy Regional Outlook (Revenue, USD Million, 2018 - 2030)
    • North America
      • North America fusion biopsy market, by biopsy route
        • Transrectal
        • Transperineal
      • North America fusion biopsy market, by end-use
        • Hospitals
        • Diagnostic centers
        • Ambulatory care centers
      • U.S.
        • U.S. fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • U.S. fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
    • Europe
      • Europe fusion biopsy market, by biopsy route
        • Transrectal
        • Transperineal
      • Europe fusion biopsy market, by end-use
        • Hospitals
        • Diagnostic centers
        • Ambulatory care centers
      • Germany
        • Germany fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Germany fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • U.K.
        • U.K. fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • U.K. fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • France
        • France fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • France fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Italy
        • Italy fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Italy fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Spain
        • Spain fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Spain fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Denmark
        • Denmark fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Denmark fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Sweden
        • Sweden fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Sweden fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Norway
        • Norway fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Norway fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
    • Asia Pacific
      • Asia Pacific  fusion biopsy market, by biopsy route
        • Transrectal
        • Transperineal
      • Asia Pacific fusion biopsy market, by end-use
        • Hospitals
        • Diagnostic centers
        • Ambulatory care centers
      • China
        • China fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • China fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Japan
        • Japan fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Japan fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • India
        • India fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • India fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Thailand
        • Thailand fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Thailand fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • South Korea
        • South Korea fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • South Korea fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Australia
        • Australia fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Australia fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
    • Latin America
      • Latin America fusion biopsy market, by biopsy route
        • Transrectal
        • Transperineal
      • Latin America fusion biopsy market, by end-use
        • Hospitals
        • Diagnostic centers
        • Ambulatory care centers
      • Brazil
        • Brazil fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Brazil fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Mexico
        • Mexico fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Mexico fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Argentina
        • Argentina fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Argentina fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
    • Middle East & Africa
      • Middle East & Africa fusion biopsy market, by biopsy route
        • Transrectal
        • Transperineal
      • Middle East & Africa fusion biopsy market, by end-use
        • Hospitals
        • Diagnostic centers
        • Ambulatory care centers
      • South Africa
        • South Africa fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • South Africa fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Saudi Arabia
        • Saudi Arabia fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Saudi Arabia fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • UAE
        • UAE fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • UAE fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers
      • Kuwait
        • Kuwait fusion biopsy market, by biopsy route
          • Transrectal
          • Transperineal
        • Kuwait fusion biopsy market, by end-use
          • Hospitals
          • Diagnostic centers
          • Ambulatory care centers

Fusion Biopsy Market Dynamics

Driver: Increasing Prevelance Of Prostate Cancer

The primary diagnostic test of prostate cancer includes prostate-specific antigen and digital rectal examination. If this preliminary test shows abnormal results, then further ultrasound imaging is recommended. However, the ultrasound scans have a high possibility to miss significant tumors, especially which are smaller in size and may cause clinical complications in the future. Therefore, urologists refrain to take risks and try to make a diagnosis as promptly and accurately as possible. This has led to the growing demand for prostate biopsy procedures contemplating its safety, reliability, and sensitivity in prostate cancer diagnosis. Thus, the demand for MR/ultrasound biopsy will grow simultaneously with the increasing prevalence of prostate cancer. Prostate cancer is the second most commonly occurring cancer in men. Thus, the high prevalence rate of prostate cancer enhances the demand for diagnostic tests and active clinical monitoring, favoring market growth.

Driver: Technological Advancements In Fusion Imaging Modalities

Frequent technological advancements are made pertaining to the hardware and software aspects of the fusion biopsy system with an intent to make them portable, effective, & safer. The advancement in software includes advanced image measurement, multiplanar image reconstruction, patient data management, and image registration tolls. All these features help streamline the operational workflow of prostate biopsy and enable them to be performed with increased precision. For instance, the MRI– ultrasound fusion biopsy system by Koelis has a patented image registration software called Organ Based Tracking fusion that works in tandem with elastic fusion technology. The unique feature of this solution is that it compensates for the continuous motion of prostate and delivers accurate 3D images of prostate.

Restraint: High Cost Of Fusion Biopsy System

There are two issues commonly reported with the implementation of a fusion biopsy system in healthcare centers. First, the technical issues arising during the merger of 2D MRI into a 3D real-time ultrasound image, which may produce a fuzzy image of the prostate. Second, the high cost of a fusion biopsy machine. The average cost of a fusion biopsy machine is unaffordable for urology centers with small capital. In addition, the cost of MRI further adds on to the final bill of the patient. Thus, the high cost is expected to hinder the installation rate of fusion biopsy system. However, benefits of targeted biopsy in the longer run such as being able to perform 4 to 5 core biopsies on a single machine, decreased need for repeat biopsy, and low pathology cost are likely to counter the restraining factor and boost market growth.

What Does This Report Include?

This section will provide insights into the contents included in this fusion biopsy market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Fusion biopsy market qualitative analysis

  • Industry overview

  • Industry trends

  • Market drivers and restraints

  • Market size

  • Growth prospects

  • Porter’s analysis

  • PESTEL analysis

  • Key market opportunities prioritized

  • Competitive landscape

    • Company overview

    • Financial performance

    • Product benchmarking

    • Latest strategic developments

Fusion biopsy market quantitative analysis

  • Market size, estimates, and forecast from 2018 to 2030

  • Market estimates and forecast for product segments up to 2030

  • Regional market size and forecast for product segments up to 2030

  • Market estimates and forecast for application segments up to 2030

  • Regional market size and forecast for application segments up to 2030

  • Company financial performance

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon